Vertex Pharmaceuticals annual gross margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Gross Margin Growth & History (VRTX)
Vertex Pharmaceuticals's gross margin was 86.24% for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 86.24% | +0.13 pp |
| 2024 | 2024-12-31 | 86.11% | −1.10 pp |
| 2023 | 2023-12-31 | 87.21% | −0.69 pp |
| 2022 | 2022-12-31 | 87.90% | −0.16 pp |
| 2021 | 2021-12-31 | 88.06% | −0.07 pp |
| 2020 | 2020-12-31 | 88.14% | +1.29 pp |
| 2019 | 2019-12-31 | 86.84% | +0.28 pp |
| 2018 | 2018-12-31 | 86.56% | −2.38 pp |
| 2017 | 2017-12-31 | 88.95% | +1.31 pp |
| 2016 | 2016-12-31 | 87.64% | −1.02 pp |
| 2015 | 2015-12-31 | 88.65% | −4.50 pp |
| 2014 | 2014-12-31 | 93.16% | +0.50 pp |
| 2013 | 2013-12-31 | 92.66% | +8.16 pp |
| 2012 | 2012-12-31 | 84.50% | −10.99 pp |
| 2011 | 2011-12-31 | 95.49% | −4.51 pp |
| 2010 | 2010-12-31 | 100.00% | — |
Vertex Pharmaceuticals quarterly gross margin
Q2.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 85.33% | −0.93 pp |
| Q1 2026 | 2026-03-31 | 86.85% | −0.05 pp |
| Q4 2025 | 2025-12-31 | 85.39% | −0.07 pp |
| Q3 2025 | 2025-09-30 | 86.52% | +0.68 pp |
| Q2 2025 | 2025-06-30 | 86.25% | +0.31 pp |
| Q1 2025 | 2025-03-31 | 86.90% | −0.37 pp |
| Q4 2024 | 2024-12-31 | 85.46% | +0.08 pp |
| Q3 2024 | 2024-09-30 | 85.84% | −1.33 pp |
| Q2 2024 | 2024-06-30 | 85.94% | −1.68 pp |
| Q1 2024 | 2024-03-31 | 87.27% | −1.49 pp |
| Q4 2023 | 2023-12-31 | 85.38% | −2.31 pp |
| Q3 2023 | 2023-09-30 | 87.17% | −0.43 pp |
| Q2 2023 | 2023-06-30 | 87.62% | −0.46 pp |
| Q1 2023 | 2023-03-31 | 88.76% | +0.48 pp |
| Q4 2022 | 2022-12-31 | 87.70% | −0.37 pp |
| Q3 2022 | 2022-09-30 | 87.60% | −0.48 pp |
| Q2 2022 | 2022-06-30 | 88.08% | +0.79 pp |
| Q1 2022 | 2022-03-31 | 88.28% | −0.57 pp |
| Q4 2021 | 2021-12-31 | 88.06% | +0.54 pp |
| Q3 2021 | 2021-09-30 | 88.08% | +0.18 pp |
| Q2 2021 | 2021-06-30 | 87.29% | −0.61 pp |
| Q1 2021 | 2021-03-31 | 88.85% | −0.43 pp |
| Q4 2020 | 2020-12-31 | 87.52% | +0.61 pp |
| Q3 2020 | 2020-09-30 | 87.90% | +1.78 pp |
| Q2 2020 | 2020-06-30 | 87.90% | +2.32 pp |
| Q1 2020 | 2020-03-31 | 89.27% | +0.35 pp |
| Q4 2019 | 2019-12-31 | 86.91% | +0.96 pp |
| Q3 2019 | 2019-09-30 | 86.11% | +0.29 pp |
| Q2 2019 | 2019-06-30 | 85.58% | −0.54 pp |
| Q1 2019 | 2019-03-31 | 88.92% | +0.10 pp |
| Q4 2018 | 2018-12-31 | 85.95% | −1.16 pp |
| Q3 2018 | 2018-09-30 | 85.82% | −1.58 pp |
| Q2 2018 | 2018-06-30 | 86.12% | −0.79 pp |
| Q1 2018 | 2018-03-31 | 88.82% | −4.60 pp |
| Q4 2017 | 2017-12-31 | 87.10% | +0.10 pp |
| Q3 2017 | 2017-09-30 | 87.40% | +0.26 pp |
| Q2 2017 | 2017-06-30 | 86.91% | −2.86 pp |
| Q1 2017 | 2017-03-31 | 93.43% | +5.93 pp |
| Q4 2016 | 2016-12-31 | 87.00% | +1.85 pp |
| Q3 2016 | 2016-09-30 | 87.14% | −3.09 pp |
| Q2 2016 | 2016-06-30 | 89.77% | −0.95 pp |
| Q1 2016 | 2016-03-31 | 87.49% | −5.73 pp |
| Q4 2015 | 2015-12-31 | 85.14% | −7.05 pp |
| Q3 2015 | 2015-09-30 | 90.23% | −4.07 pp |
| Q2 2015 | 2015-06-30 | 90.72% | −2.30 pp |
| Q1 2015 | 2015-03-31 | 93.23% | +0.46 pp |
| Q4 2014 | 2014-12-31 | 92.19% | −4.03 pp |
| Q3 2014 | 2014-09-30 | 94.30% | +3.34 pp |
| Q2 2014 | 2014-06-30 | 93.02% | +0.97 pp |
| Q1 2014 | 2014-03-31 | 92.76% | +2.19 pp |
| Q4 2013 | 2013-12-31 | 96.22% | +18.85 pp |
| Q3 2013 | 2013-09-30 | 90.96% | +0.09 pp |
| Q2 2013 | 2013-06-30 | 92.05% | +17.05 pp |
| Q1 2013 | 2013-03-31 | 90.57% | −3.52 pp |
| Q4 2012 | 2012-12-31 | 77.37% | −18.56 pp |
| Q3 2012 | 2012-09-30 | 90.87% | −3.78 pp |
| Q2 2012 | 2012-06-30 | 75.01% | −20.27 pp |
| Q1 2012 | 2012-03-31 | 94.09% | −5.91 pp |
| Q4 2011 | 2011-12-31 | 95.93% | — |
| Q3 2011 | 2011-09-30 | 94.65% | — |
| Q2 2011 | 2011-06-30 | 95.28% | −4.72 pp |
| Q1 2011 | 2011-03-31 | 100.00% | — |
| Q2 2010 | 2010-06-30 | 100.00% | — |
Vertex Pharmaceuticals gross margin trends
Over the last five fiscal years, Vertex Pharmaceuticals's gross margin decreased from 88.14% to 86.24%, a change of −1.89 percentage points. The latest reported quarter, Q2 2026, shows 85.33%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
